Novo Nordisk’s Wegovy Gets A Logistics Boost – EU Eases Shipping Rules

Novo Nordisk (NVO) on Thursday announced that the European Medicines Agency approved flexible delivery conditions for its blockbuster Wegovy injection, allowing transport at up to 30°C for up to 48 hours, potentially easing supply chain constraints for GLP-1 treatments.

NVO shares are down 1.4% in pre-market trading.

The change is expected to simplify distribution by reducing reliance on cold chain logistics, potentially lowering delivery costs and improving supply chain efficiency for pharmacies and online providers.

Novo added that there are no changes to patient use guidelines, and the update applies only to the Wegovy injection, not the pill, which is currently pending an EU regulatory decision.

Get updates to this story on Stocktwits.

For updates and corrections, email newsroom[at]stocktwits[dot]com.